Terren Peizer
Terren Scott Peizer, is an investor and company executive. He is the CEO of Acuitas Group Holdings and Neurmedix.[1] He is also the CEO and chairman of Ontrak.[2] He has held senior executive positions within technology and biotech companies, at Goldman Sachs and First Boston,[1] and as a bond salesman at Drexel Burnham Lambert.[3][4]
Terren Scott Peizer | |
|---|---|
| Born | |
| Alma mater | Wharton School of the University of Pennsylvania |
| Occupation | Financier |
| Website | www |
Early life and education
Peizer's hometown is Beachwood, Ohio.[5] He attended Beachwood High School.[6] Peizer graduated from the Wharton School of the University of Pennsylvania.[1]
Career
In 1983, Peizer worked at Goldman Sachs[1] and later worked at First Boston as a salesman. Michael Milken hired Peizer as a bond salesman at Drexel Burnham Lambert in 1985.[7] He was the manager of David M. Solomon's account with Drexel[5] and given a 3.5 million dollar salary and a $500.000 loan to invest in the partnership.[8] Peizer worked directly under (and at the same desk as) Milken and admired him, sometimes pretending to be him on the phone, and calling him "Dad".[9] When investigations into Milken's illegal activities started, Peizer agreed to provide material evidence to prosecutors in exchange for immunity.[10]
In 1989 Peizer purchased the Omaha Racers, a minor league basketball team.[11] In 1991 he bought UTI Chemicals Inc. through his company Financial Group Holdings Inc.[12] and stepped down as its chairman in 1994.[13]
In 1993 he was elected Chairman at CMS Enhancements after acquiring a 36.8% share of the company.[14] From 1997 to 1999, Peizer was president of Hollis-Eden, a pharmaceutical company.[15][16] In 1999 Peizer raised money for Tera Computer Company, a manufacturer of supercomputers, which allowed them to later buy out Cray Research and became its chairman and a director.[17] He stepped back down as chairman in 2000 because the company was concerned that he would not obtain a security clearance from the United States Department of Defense by the end of 2000 to transfer Cray's classified business from Silicon Graphics, causing Cray Research to pay a penalty fee to Silicon Graphics.[18]
Peizer founded Hythiam Inc., a pharmaceutical company, in 2004.[19] The firm bought the rights to Juan Jose Legarda's addiction treatment pharmaceuticals.[20] 60 Minutes and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing Prometa to market.[21][22]
In 2018, Peizer became CEO and director of BioVie, a pharmaceutical company.[23]
References
- ^ a b c d "Catasys Inc (CATS.OQ)". Reuters. Retrieved 2020-11-25.[dead link]
- ^ Hackett, Mallory (2020-11-03). "Ontrak deepens its behavioral health platform with LifeDojo acquisition". MobiHealthNews. Retrieved 2020-11-25.
- ^ Labaton, Stephen (1988-12-10). "4th Drexel Employee in Immunity Bargain". The New York Times. ISSN 0362-4331. Retrieved 2020-11-25.
- ^ Eichenwald, Kurt (20 October 1990). "Kohlberg, Kravis Official Tells of a Hidden Milken Stake". The New York Times.
- ^ a b Lee, Patrick (1994-07-31). "In the Shadow of the '80s : Yesterday's High Rollers Struggle in a New Era of Sobriety". Los Angeles Times. Retrieved 2020-11-26.
- ^ Polien Light, Nina (May 8, 2008). "An entrepreneur with heart". Cleveland Jewish News. Retrieved February 6, 2022.
- ^ Eaton, Leslie (17 February 1998). "No Sales, but Watch the Stock Soar". The New York Times.
- ^ Kornbluth, Jesse. Highly confident: The Crime and Punishment of Michael Milken. p. 213.
- ^ Griffin, Nancy; Masters, Kim (12 January 2016). Hit & Run: How Jon Peters and Peter Guber Took Sony for a Ride in Hollywood. ISBN 9781439128046.
- ^ Labaton, Stephen (10 December 1988). "4th Drexel Employee in Immunity Bargain". The New York Times.
- ^ "Omaha CBA team sold to Los Angeles banker". The Lincoln Star. 7 September 1989. p. 18. Retrieved 11 August 2020.
- ^ Michaud, Anne (1991-04-10). "Drexel Figure Gains Control of UTI Chemicals". Los Angeles Times. Retrieved 2020-11-25.
- ^ "Jim Orefice has been appointed chairman..." Los Angeles Times. 1994-02-07. Retrieved 2020-11-26.
- ^ "CMS Enhancements Names New Top Management Team". LA Times. 10 December 1993.
- ^ Eaton, Leslie (17 February 1998). "Market Place; No Sales, but Watch the Stock Soar". The New York Times.
- ^ "Small world, ain't it?". Forbes. 1999-09-05. Retrieved 2020-11-25.
- ^ "L.A. Financier Reemerges as Key Player in Cray Deal". Los Angeles Business Journal. 5 March 2000.
- ^ "Technology Briefs". Wall Street Journal. 2000-12-26. ISSN 0099-9660. Retrieved 2020-11-25.
- ^ Bartholomew, Dana (7 December 2018). "Catasys Thrives on Data Dives". Los Angeles Business Journal. Retrieved 12 August 2020.
- ^ Alpert, Bill. "Curb Your Cravings For This Stock". Barrons. Retrieved 2020-11-26.
- ^ . 60 Minutes. CBS News. December 9, 2007. Archived from the original on 2007-12-31. Retrieved 2008-08-22.
- ^ Ramshaw, Emily (January 20, 2008). . Dallas Morning News. Archived from the original on 2010-10-27.
- ^ Iral, Vince (2018-07-04). "BioVie sells stock, warrants to Acuitas, names CEO". S&P Global. Retrieved 2020-11-25.